ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OTIC Otonomy Inc

0.077
0.00 (0.00%)
12 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Otonomy Inc NASDAQ:OTIC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.077 0.0757 0.0777 0 00:00:00

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

18/07/2022 12:30pm

GlobeNewswire Inc.


Otonomy (NASDAQ:OTIC)
Historical Stock Chart


From Feb 2022 to Feb 2025

Click Here for more Otonomy Charts.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022. 

A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

About Otonomy  Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com. 

Contacts:

Media Inquiries:Spectrum ScienceLauren BentonSenior Account Executive212.899.9731lbenton@spectrumscience.com

Investor Inquiries:ICR WestwickeRobert H. UhlManaging Director858.356.5932robert.uhl@westwicke.com 

1 Year Otonomy Chart

1 Year Otonomy Chart

1 Month Otonomy Chart

1 Month Otonomy Chart

Your Recent History

Delayed Upgrade Clock